Health Catalyst Inc stock (US42226A1079): Insider share sale surfaces as earnings backdrop stays in focus

Health Catalyst shares on Nasdaq remain under the spotlight after a recent insider share sale filing in the United States, with investors also keeping an eye on the latest quarterly earnings trends from the Utah-based data and analytics group.

Health Catalyst shares on the Nasdaq in the United States continue to attract attention after recent filings flagged insider share sale activity, while the market still digests the most recent quarterly earnings profile of the healthcare data and analytics specialist.

The stock most recently traded in the low-single-digit dollar range on Nasdaq under the ticker HCAT, with trading in US dollars and intraday moves reflecting broader sentiment toward health technology names, according to price data from exchange and market-data providers as of late May 2026.

A recent regulatory filing referenced by specialist platforms shows that an insider-related transaction involved tens of thousands of dollars in proceeds from Health Catalyst stock, underlining that equity-based compensation remains an important element of management remuneration at the company.

The same filing information indicates that restricted shares tied to performance targets have been a component of the equity grants, which can result in share sales when vesting conditions are met and windows for trading are open, according to the summary of the Form 144 disclosure.

As a US-listed company, Health Catalyst falls under US Securities and Exchange Commission oversight, and insider transactions such as planned sales of restricted stock are typically reported via SEC forms that become public, providing transparency to investors reviewing the ownership and governance profile.

For investors following the name from Europe, Health Catalyst can also be traded on German off-exchange venues such as Tradegate via secondary listings in euros, although the primary market and reference price remain anchored on the US Nasdaq platform where liquidity is highest.

The most recent quarterly earnings release from Health Catalyst, filed in the United States earlier in 2026, set out revenue growth and operating metrics in its data platform and services businesses, framing the narrative for the current financial year and forming the basis for how the market evaluates progress relative to prior periods.

That update outlined trends in subscription and professional services revenue, along with key profitability indicators such as adjusted EBITDA and net loss per share, giving a snapshot of how the company is balancing investment in growth with a path toward improved operating leverage over time.

On the corporate events side, Health Catalyst maintains an active calendar of investor engagement, including earnings conference calls and participation in healthcare and technology conferences, as highlighted in the company event overviews for 2026.

These scheduled appearances give management the chance to discuss strategic priorities, comment on demand from health system clients, and respond to questions on capital allocation, providing additional color beyond the headline numbers in quarterly reports.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: HCAT
• Sector/industry: Healthcare data analytics and software
• Headquarters/country: Salt Lake City, United States
• Core markets: United States health systems and payers, selected international clients
• Key revenue drivers: Data platform subscriptions, analytics software, professional and advisory services to healthcare providers and payers
• Home exchange/listing venue: Nasdaq (HCAT)
• Trading currency: USD

Health Catalyst Inc: core business model

Health Catalyst operates as a healthcare-focused data and analytics specialist, providing a cloud-enabled platform and related services that help hospitals and payers use clinical and financial data to improve outcomes and efficiency, with revenue mainly generated from software subscriptions and advisory engagements.

Latest quarterly results for Health Catalyst Inc at a glance

Health Catalyst’s latest reported quarter in early 2026 showed continued revenue contributions from its data platform and professional services operations, according to company financial disclosures and earnings materials released in the United States.

The quarterly update detailed how recurring software and technology-enabled services underpin the top line, while management continues to work on narrowing losses and improving adjusted profitability metrics over time.

Conclusion

The latest insider share sale filings and ongoing secondary-market trading activity keep Health Catalyst in focus on its US home exchange, with transparency around equity-based compensation adding an extra layer of information for governance-minded investors.

At the same time, the most recent quarterly results provide the financial context against which the market will judge the company’s progress in scaling its healthcare analytics platform and moving its business model toward greater operating efficiency.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.